Open RFP

TECHNOLOGY LICENSING OPPORTUNITY: DC Recruiter RFP

Description: DC Recruiter: Broad-Spectrum Immune Enhancer from scientists at Laboratory offers a differentiated approach to multi-pathogen infection prevention by using a self-assembling peptide nanofiber to recruit and activate dendritic cells (DCs), the immune system’s natural sentinels. Unlike pathogen-specific vaccines or therapeutics, it is designed to help trigger an early immune response regardless of the infecting agent. Its needle-free, spray-friendly concept adds practicality.

Buyer: Triad National Security (Los Alamos) (Contractor)
Federal · NM, US
Released: Jun 15, 2026
Closes: Dec 15, 2026(130 days left)

Files

Original attachments and procurement documents tied to this bid.

Federal RFP files are for Starbridge customers only.

You can request RFP files from all other buyer types for free on this site.

Key Contacts

Procurement and program contacts connected to Triad National Security (Los Alamos) (Contractor).

Steven ColemanAssociate Laboratory Director, Environment, Safety, Health and Quality

*******@************

+1 (***) ***-****

Elaine SchuckChief Information Security Officer

*******@************

+1 (***) ***-****

Nathan /reasoning: The given fullName contains exactly two parts: a first name (Nathan) and a last name (Moody). No middle name is present. MoodyDirector, Entrepreneurship for Mission Innovation

*******@************

+1 (***) ***-****

Rachel Byars SchroederDirector of Internal Audit & Ethics

*******@************

+1 (***) ***-****

Similar active RFPs

Adjacent opportunities open for bidding right now.

Triad National Security (Los Alamos) (Contractor)
FederalNM
Open
Jun 17, 2026
Closes
Dec 17, 2026
TECHNOLOGY LICENSING OPPORTUNITY: NanoFET RFP
NanoFiber Engineered Therapeutics Platform (NanoFET) from Laboratory offers pharmaceutical and biodefense organizations a modular, adaptable scaffold for building next-generation immunotherapies. By merging self-assembling peptide nanofibers with interchangeable nanobody and peptide components, the platform enables rapid development of targeted treatments that bridge disease agents directly to the patient’s own immune cells.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Open
Jun 5, 2026
Closes
Dec 5, 2026
TECHNOLOGY LICENSING OPPORTUNITY: SurfGraphPro RFP
SurfGraphPro, an AI tool, transforms complex protein structures into an easy-to-analyze format that helps researchers quickly identify binding sites, predict molecular interactions and understand protein behavior with greater speed and scalability than traditional approaches. By combining 3D surface graph representations with advanced machine learning, this technology from Los Alamos National Laboratory reduces the computational burden of protein analysis while preserving the structural detail needed for high-value applications in drug discovery, antibody design, pathogen detection and custom protein engineering.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Open
Jun 8, 2026
Closes
Dec 8, 2026
TECHNOLOGY LICENSING OPPORTUNITY: M-Resistor RFP
M-Resistor, developed by Laboratory, offers pulsed power operators a more protective and more inspectable way to manage reflected energy in high-voltage systems.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Open
Jun 4, 2026
Closes
Dec 3, 2026
TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform RFP
A novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations.

See your top accountsScan your site in seconds. Starbridge identifies your ICP and surfaces emerging opportunities from board meetings, job changes, new grants, contract expirations, RFPs, and more.

See your top 10 accounts